Efficacy: Success with less invasive ventilation

CUROSURF® (poractant alfa) Intratracheal Suspension administration facilitates transition from
mechanical ventilation (MV)

The table below details the studies in which CUROSURF® (poractant alfa) Intratracheal Suspension was used in conjunction with less invasive ventilation. In each study, the addition of CUROSURF to NCPAP helped a majority of infants stay on less invasive ventilation avoiding the need for reintubation or subsequent MV.1-4

Table of study findings with NCPAP use and CUROSURF administration
The Verder 1994 study compared the success rates of infants receiving CUROSURF + NCPAP vs NCPAP alone. Patients who received CUROSURF in conjunction with NCPAP experienced significantly higher success rates vs NCPAP alone.1

In later studies examining the timing of surfactant administration, a greater number of patients achieved success when CUROSURF was administered early vs late.2,3

*NCPAP = nasal continuous positive airway pressure.
†Success with NCPAP was defined as no further need to reintubate for subsequent MV or surfactant redosing.
‡Late surfactant administration was defined as after FiO2 had risen to 0.57–0.77.2

About the INSURE method: INtubate → SURfactant → Extubate
The INSURE method of stabilizing infants with RDS involves early surfactant administration followed by rapid extubation to NCPAP. In two recent studies of CUROSURF using the INSURE method, at least 81% of infants were able to successfully avoid subsequent MV and reintubation.3,4

Next: Leading the Way

Also take a look at how CUROSURF® (poractant alfa) Intratracheal Suspension demonstrates a rapid onset of action and sustained results with fewer doses for fast RDS success.

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

CUROSURF facilitates efficient administration.
Learn More
Interested in evaluating CUROSURF? Find out how you can smoothly integrate CUROSURF into your NICU by participating in the CUROSURF Experience Program.
Learn More

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS)
in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is recommended prior to CUROSURF administration. Surfactant administration can be expected to reduce the severity of RDS but will not eliminate the mortality and morbidity associated with other complications of prematurity.

Pulmonary Hemorrhage is a known complication of premature birth and very low birth-weight and has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700-2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

Please see full prescribing information.

This site is intended for United States residents only.

References: 1. Verder H, Robertson B, Greisen G, et al; for The Danish-Swedish Multicenter Study Group. N Engl J Med. 1994;331:1051-1055. 2. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6. 3. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:e560-e563. 4. Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. J Perinatol. 2007;27:422-427.